Non-Hodgkin lymphoma (NHL) affects about 2.1% of the population with an estimated 661,996 patients with NHL. It accounts for 4.3% of new cancer diagnoses, and 3.4% of cancer deaths. It is more prevalent in men than in women. 1 With treatment, 71% of patients with NHL survive to 5 years. NHL is responsible for 20,140 deaths annually. The direct medical cost to Medicare per case per year due to treatment of NHL is about $49,000 annually. 2 NHL is more common in patients with immunosuppressed states, such as transplant recipients, AIDS patients, and patients on chronic glucocorticoids.
Current Treatment
NHL can be treated with radiation therapy, chemotherapy, and biologic therapy. The specific type of therapy depends on the type of NHL. Indolent NHL is frequently treated with a single agent. Aggressive NHL is generally treated with complex combination chemotherapy and biologic therapy. Many types of NHL are treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), given in 4 to 6 cycles. 3 R-CHOP has many short-and long-term toxicities, including increased risk of infection, bruising and bleeding, mucositis, and cardiotoxicity. About 40% to 50% of patients with diffuse large B-cell lymphoma will relapse or not respond following treatment with R-CHOP. 4 The side effect profile and relatively high rate of relapse and nonresponse to this first-line treatment suggest the need for new therapeutic strategies.
New Treatment Options
Chimeric antigen receptor T-cell (CAR T-cell) therapy is a term that describes a range of immunotherapies. In essence, CAR T-cell therapy uses autologous T cells, which are modified with a vector to produce a CAR specific to a tumor antigen, creating a T cell that is designed to attack cells bearing that antigen. In theory, this strategy could be applied to any tumor antigen, but the products closest to market all target CD19 (Table 1 ). CD19 is expressed on the surface of B cells, so B cell leukemias and lymphomas are the target of these CAR T products. 5 In one phase II trial, axicabtagene induced complete remission of NHL in 54% of patients at 6 months. Tisagenlecleucel showed 82% complete remission of refractory B-cell acute lymphoblastic leukemia (ALL) in a phase II study. All drugs in this class have the adverse effect of cytokine release syndrome (CRS), with about one-third of patients having severe CRS. One CAR T-cell product, JCAR015, was abandoned due to patient deaths during trials due to CRS and cerebral edema. Tisagenlecleucel has also caused B-cell aplasia, requiring treatment with intravenous immunoglobulin (IVIG). These safety concerns are the primary barrier to potential Food and Drug Administration (FDA) approval Hospital Pharmacy 52 (7) of CAR T-cell products. These products will likely be priced up to $500,000 per treatment course based on analyst predictions. 6 An analysis by the United Kingdom's National Institute for Health and Care Excellence suggested that these therapies could be worth up to $649,000 for young patients with acute lymphoblastic leukemia. 7 The CRS side effect has generally been treated in clinical trials with tocilizumab, which adds to the cost of this therapy. Tocilizumab costs about $1000 per dose. IVIG costs between $1000 and $10,000 per dose.
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An FDA subcommittee recommended approval of tisagenlecleucel in a 10-0 vote on 7/12/17, with a PDUFA date of 10/3/17. Novartis is estimating the manufacturing turn-around time to be 22 days, which includes 10 to 12 days for cell processing. In a 50-patient phase II trial, 82% of patients achieved a complete response. In a 60-patient ALL trial, overall survival was 65% at 24 months. JCAR017
Juno Therapeutics CD19 Analysts estimate that JCAR017 may be available in mid-2018. Juno plans a phase III trial in DLBCL patients in the second half of 2017. In a 44-patient trial, 66% of patients had an objective response, and 50% achieved a complete response. bb2121
bluebird bio BCMA Bluebird announced that interim results from a phase I trial showed that 15 of 15 patients with relapsed multiple myeloma achieved an objective response.
LCAR-B38M
Nanjing Legend Biotech BCMA Legend announced that interim results from a phase I Chinese trial showed that 33 of 35 patients with relapsed multiple myeloma achieved clinical remission within 2 months.
